cabazitaxel
emcure,sanofi
['crpc', 'cabazitaxel']
michael hofman reports psa responses and pfs benefit but no survival benefit with psma-lut-617 compared with cabazitaxel for mcrpc. concluding similar os but differing adverse effect profile. #asco22 
Prostate cancer medical oncologist and physician-scientist, Kendrick Family Chair for Prostate Cancer Research, Cleveland Clinic. Posts are my own.